@article{3192218,
    title = "Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or
with chemotherapy (pembro plus C) vs EXTREME (E) as first-line (1L)
therapy for recurrent/metastatic (R/M) head and neck squamous cell
carcinoma (HNSCC)",
    author = "Greil, R. and Rischin, D. and Harrington, K. J. and Soulieres, D. and and Tahara, M. and de Castro, G. and Psyrri, A. and Baste, N. and Neupane, and P. and Bratland, A. and Fuereder, T. and Hughes, B. G. M. and Mesia, and Sr., R. and Ngamphaiboon, N. and Rordorf, T. and Ishak, W. Z. Wan and and Lin, J. and Swaby, R. F. and Gumuscu, B. and Burtness, B.",
    journal = "Annals of Oncology",
    year = "2020",
    volume = "31",
    number = "4",
    pages = "S660-S661",
    publisher = "Elsevier",
    issn = "0923-7534, 1569-8041",
    doi = "10.1016/j.annonc.2020.08.1030"
}